Shkreli Planet — searchable YouTube transcripts & AI Q&A

Martin Shkreli Gives His Life To Jesus And Preaches About Neoclouds & AI

Martin Shkreli delivers a satirical biblical sermon, recasting tech and AI industry hype as a parable of financial excess and inevitable collapse. He argues that the current AI boom, driven by massive borrowing and inflated expectations, will end in a bubble burst, as evidenced by his mockery of 'adjusted earnings' and the reliance on nonexistent citations. He warns against building on forecasts that require universal premium subscriptions and counting the same silver multiple times through partnerships.

Martin Shkreli Tries To Understand How Moderna Is Worth $90 Billion – Full Analysis

Martin Shkreli argues that Moderna's $94 billion valuation is unjustified, as even a wildly optimistic scenario where its cancer vaccine becomes the best-selling drug ever only supports a share price around $100, far below the current $235. He models the company's value based on its lead asset, mRNA-4157, and concludes that reaching the current price would require $25 billion in revenue, which he deems highly speculative. He also notes that the company's RSV vaccine is underperforming, adding to his bearish thesis.

Martin Shkreli Gives Advice To Investors/Traders

Martin Shkreli argues that successful investing comes from having multiple distinct strategies or 'toolkits' rather than relying on one approach. He illustrates this by contrasting trend-following, which he dislikes because it's crowded and priced in, with finding undiscovered small-cap stocks or making concentrated bets on disruptive technologies like Revolution Medicines. He also notes that even a simple strategy like buying products you love can work, but emphasizes the importance of adapting and adding new tools over time.

Martin Shkreli Explains Why Investing in Biotech Is Hard

Investing in biotech is difficult because stock prices often move for reasons unrelated to the company's fundamentals, such as sector sentiment and competition from other industries like AI, argues Martin Shkreli. He uses Spruce Biosciences as an example, explaining that while its enzyme replacement therapy for San Filippo is likely to gain approval and generate high revenue per patient, the stock may still languish until broader market conditions favor biotech. Patience is key, as it can take years for the stock to reflect the company's value.

Martin Shkreli On Why AI Won’t Cure Diseases

Martin Shkreli argues that AI will not accelerate drug development or cure diseases because the bottleneck is not molecule design or drug discovery, which he says is the easiest part, but rather the mandatory clinical trial process. He contends that good drugs already get approved quickly and that AI's role is limited to helping sift through paperwork, not in creating treatments. He dismisses the idea that AI can solve the physical-world challenges of medicine.